EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib

BMC Bioinformatics

Lichun Ma¹  Debby D Wang¹  Yiqing Huang³  Hong Yan¹  Maria P Wong²  Victor HF Lee² 

[1] Department of Electronic Engineering, City University of Hong Kong, Kowloon, Hong Kong

[2] Li Ka Sing Faculty of Medicne, University of Hong Kong, Pokfulam, Hong Kong

[3] School of Computer Science and Technology, Soochow University, Suzhou, China

关键词: Binding free energy;    Erlotinib;    Gefitinib;    Tyrosine kinase inhibitor;    Non-small-cell lung cancer (NSCLC);    EGFR mutation database;    Epidermal growth factor receptor (EGFR);   

Others  :  1139035
DOI  :  10.1186/s12859-015-0522-3

 received in 2014-10-21, accepted in 2015-02-27,  发布年份 2015

【 摘 要 】

Background

Epidermal growth factor receptor (EGFR) mutation-induced drug resistance has caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However, structural information is available for just a few EGFR mutants. In this study, we created an EGFR Mutant Structural Database (freely available at http://bcc.ee.cityu.edu.hk/data/EGFR.html webcite), including the 3D EGFR mutant structures and their corresponding binding free energies with two commonly used inhibitors (gefitinib and erlotinib).

Results

We collected the information of 942 NSCLC patients belonging to 112 mutation types. These mutation types are divided into five groups (insertion, deletion, duplication, modification and substitution), and substitution accounts for 61.61% of the mutation types and 54.14% of all the patients. Among all the 942 patients, 388 cases experienced a mutation at residue site 858 with leucine replaced by arginine (L858R), making it the most common mutation type. Moreover, 36 (32.14%) mutation types occur at exon 19, and 419 (44.48%) patients carried a mutation at exon 21. In this study, we predicted the EGFR mutant structures using Rosetta with the collected mutation types. In addition, Amber was employed to refine the structures followed by calculating the binding free energies of mutant-drug complexes.

Conclusions

The EGFR Mutant Structural Database provides resources of 3D structures and the binding affinity with inhibitors, which can be used by other researchers to study NSCLC further and by medical doctors as reference for NSCLC treatment.

【 授权许可】

   
2015 Ma et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 6.

Figure 6.

【 参考文献 】

• [1]Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
• [2]Wang H, Xing F, Su H: Novel image markers for non-small cell lung cancer classification and survival prediction. BMC Bioinform 2014, 15(1):310. BioMed Central Full Text
• [3]Okamoto W, Okamoto I, Tanaka K, Arao T, Nishio K, Fukuoka M: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Cancer Res 2011, 71(8 Supplement):1731.
• [4]Bar J, Onn A: Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. Clin Lung Cancer 2012, 13(4):267-279.
• [5]Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC: Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2011, 72(2):205-212.
• [6]Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
• [7]Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. BioMed Res Int 2011; doi:10.1155/2011/165214.
• [8]Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17(6):1616-1622.
• [9]Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z: Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007, 28(8):760-770.
• [10]Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP: Association of Exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. J Thorac Oncol 2013, 8(9):1148-1155.
• [11]The Protein Data Bank. [http://www.rcsb.org]
• [12]Yang LW, Eyal E, Chennubhotla C, Jee J, Gronenborn AM, Bahar I: Insights into equilibrium dynamics of proteins from comparison of NMR and X-ray data with computational predictions. Structure 2007, 15(6):741-749.
• [13]Hao GF, Yang GF, Zhan CG: Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem. Drug Discov Today 2012, 17(19):1121-1126.
• [14]Cao ZW, Han LY, Zheng CJ, Ji ZL, Chen X, Lin HH: Computer prediction of drug resistance mutations in proteins. Drug Discov Today 2005, 10(7):521-529.
• [15]Wang DD, Zhou W, Yan H, Wong M, Lee V: Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Sci Rep 2013, 3:2855.
• [16]Yarov‐Yarovoy V, Schonbrun J, Baker D: Multipass membrane protein structure prediction using Rosetta. Proteins 2006, 62(4):1010-1025.
• [17]Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R: ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 2011, 487:545-574.
• [18]Zhou W, Wang DD, Yan H, Wong M, Lee V: Prediction of anti-EGFR drug resistance base on binding free energy and hydrogen bond analysis. Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) 2013, 193-197.
• [19]Case DA: AMBER 12. University of California, San Francisco; 2012.
• [20]Kellogg EH, Leaver‐Fay A, Baker D: Role of conformational sampling in computing mutation‐induced changes in protein structure and stability. Proteins 2011, 79(3):830-838.
• [21]Kortemme T, Baker D: A simple physical model for binding energy hot spots in protein–protein complexes. Proc Natl Acad Sci 2002, 99(22):14116-14121.
• [22]Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Šali A: Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomo Struct 2000, 29(1):291-325.
• [23]Ginalski K: Comparative modeling for protein structure prediction. Curr Opin Struct Biol 2006, 16(2):172-177.
• [24]Sanchez R, Šali A: Advances in comparative protein-structure modelling. Curr Opin Struct Biol 1997, 7(2):206-214.
• [25]Pieper U, Webb BM, Barkan DT, Schneidman-Duhovny D, Schlessinger A, Braberg H: ModBase, a database of annotated comparative protein structure models, and associated resources. Nucl Acids Res 2011, 39(suppl 1):D465-D474.
• [26]Xiang Z: Advances in homology protein structure modeling. Curr Protein Pept Sci 2006, 7(3):217-227.
• [27]Thompson JD, Gibson T, Higgins DG. Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinform 2002; doi:10.1002/0471250953.bi0203s00.
• [28]McGuffin LJ, Bryson K, Jones DT: The PSIPRED protein structure prediction server. Bioinform 2000, 16(4):404-405.
• [29]Rohl CA, Strauss CE, Misura KM, Baker D: Protein structure prediction using Rosetta. Methods Enzymol 2004, 383:66-93.
• [30]Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC: UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(13):1605-1612.
• [31]Bamford S, Dawson E, Forbes S, Clements J, Pettet R, Dogan A: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004, 91(2):355-358.
• [32]Yadav IS, Singh H, Imran KM, Chaudhury A, Raghava GP, Agarwal SM: EGFRIndb: Epidermal Growth Factor Receptor Inhibitor Database. Anti-cancer Agents Med Chem 2014, 14(7):928-35.
• [33]Ma L, Wang DD, Huang Y, Wong MP, Lee VH, Yan H. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties. Comput Biol Med. 2014; doi:10.1016/j.compbiomed.2014.06.016